{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "4f3d13f2dae79e021f9f1eba85696afd",
    "title": "Jefferies",
    "source_uri": "2025-08-31/Week Ahead ICIEM SGMO ASBMR RAREMREOTYRA WCLC IDYAWeek Ahead ICIEM SGMO ASBMR RAREMREOTYRA WCLC IDYA_2025-08-31",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-27T00:45:18.576697",
      "extracted_at": "2025-10-27T00:45:18.576707"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 12,
        "successful_pages": 12,
        "date": "2025-08-31",
        "publication": "2025-08-31",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 11,
          "reduction_ratio": 0.2906527029375978
        },
        "input_relative_path": "2025-08-31"
      }
    }
  },
  "passages": [
    {
      "passage_id": "0b3f84b840d0185f",
      "text": "Week Ahead: ICIEM (SGM) ASBMR (RARE/ MREO/TYRA); WCLC (HRA)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "e47339b1b579115b",
      "text": "ESC (Aug 29- Sept 1) continues this wk. ICIEM (Sept 2- 6) is this wk - SGMO will present add'l ph.I/II Fabry data (stock \\(+20\\% / - 10\\%\\) ; POS \\(75\\%\\) ). ASBMR (Sept 5- 8) starts this wk; we will look at titles relevant to RARE/MREO (OI) & TYRA (ACH). WCLC (Sept 6- 9) also starts this wk w/ titles relevant to IDYA/TNGX/ ORIC/ERAS; IDYA's partner Hengrui will present clin updates for IDE849 DLL3- ADC ph.I SCLC on Sept 7 (stock \\(+20\\% / - 10\\%\\) ; POS \\(70\\%\\) ).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b545ba3d91f4c78d",
      "text": "European Society of Cardiology (ESC; Aug 29- Sept 1); titles & regular abstracts here International Congress of Inborn Errors of Metabolism (ICIEM) joint conference with ASIEM, JSIMD, SIMD, SLEIMPN, & SSIEM (Sept 2- 6): program & titles here; abstracts available to registered attendees SGMO will present add'l clinical data of ST- 920 ph.I/II Fabry disease (P- 662) (stock \\(+20\\% / - 10\\%\\) ; POS \\(75\\%\\) ). American Society of Bone and Mineral Research (ASBMR; Sept 5- 8): regular & LBA titles here; abstracts available to registered attendees We highlighted regular titles (here) & LBA titles (here) relevant to RARE/MREO (OI) & TYRA (achondroplasia). IASLC World Conference on Lung Cancer (WCLC; Sept 6- 9): regular & LBA titles+regular abstracts here (except embargoed abstracts) We highlighted regular titles (here) & LBA titles (here) relevant to our coverage (IDYA/TNGX/ORIC/ERAS). IDYA- related: Partner Hengrui will present clinical updates for IDE849/SHR- 4849 (DLL3- ADC) ph.I SCLC study in China on Sept 7 @10:47AM ET (OA06.01A) (stock \\(+20\\% / - 10\\%\\) ; POS \\(70\\%\\) ).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "48283925522b707c",
      "text": "American College of Rheumatology (ACR; Oct 24- 29): program here; regular titles & abstracts post early- Sept; LBA titles+abstracts post early- Oct (embargo lift Oct 25 @11AM ET)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "633251275558e6a1",
      "text": "ALNY: started recruiting at 2 add'l sites (13 recruiting sites in total) for ALN- BCAT in ph.I HCC \\((n = 15\\) NCT06600321) as of 8/26 ALNY: started recruiting at 5 add'l sites (44 recruiting sites in total) for ALN- APP in ph.II cerebral amyloid angiopathy (cAPPicrom- 1) \\((n = 200\\) NCT06393712) as of 8/29 KALV: completed recruiting at 10 sites (8 recruiting sites in total) for sebetralstat in pediatric (2- 11yo) HAE (KONFIDENT- KID) \\((N = 36\\) NCT06467084) as of 8/28 MRUS: started recruiting at 1 add'l site (161 recruiting sites in total) for peto mono in ph.II 2L/3L HNSCC \\((n = 500\\) NCT06496178) as of 8/29 MRUS: started recruiting at 10 add'l sites (154 recruiting sites in total) for peto+pembro in ph.II 1L HNSCC (LiGeR- HN1) \\((n = 500\\) NCT06525220) as of 8/29 NTLA: started recruiting at 5 add'l sites (124 recruiting sites in total) for NTLA- 2001 in ph.II ATTR- CM (MAGNITUDE) \\((n = 765\\) NCT06128629) as of 8/29",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d425ef3742dedc7d",
      "text": "SLDB: started recruiting at 1 add'l site (10 recruiting sites in total) for SGT- 003 in ph.I/II DMD (INSPIRE DUCHENNE) \\((n = 40\\) , NCT06138639) as of 8/24 SLDB: started a ph.I for SGT- 501 in catecholaminergic polymorphic ventricular tachycardia (CPVT) (ARTEMIS) \\((n = 18\\) , NCT07148089) as of 8/29 TNGX: started recruiting at 1 add'l site (7 recruiting sites in total) for TNG456 in ph.I/II solid tumors w/ MTAP loss \\((n = 191\\) , NCT06810544) as of 8/29 TNGX: started recruiting at 1 add'l site (5 recruiting sites in total) for TNG462+RMC- 9805 or RMC- 6236 in ph.I/II PDAC & NSCLC w/ MTAP loss & RAS mutation \\((n = 133\\) , NCT06922591) as of 8/29",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "ba9f79ed88f337e8",
      "text": "ARWR: Plozasiran FCS PDUFA 11/18/25 VERA- related: Otsuka's sibeprenlimab IgAN PDUFA 11/28/25 TYRA- related: ASND TransCon CNP Achondroplasia PDUFA 11/30/25 w/ priority review",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "c38995a77e39fe49",
      "text": "...CONTINUE ON BACK PAGES FOR REGULATORY TRACKER, NEAR- TERM CATALYSTS, UPCOMING MED CONFS, & RECENT REPORTS",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "785285b45b461314",
      "text": "BCRX: Orladeyo pediatric (2- 11yo) HAE oraphy PDUFA 12/12/25 TVTX: Filspari FSGS PDUFA 1/13/26 Com likely in 4Q (JEF est)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "cb7eb4d21f7fb7d7",
      "text": "ARWR: Readthroughs from IONS' pivotal CORE/CORE2 data in SHTG in Sept'25 (stock \\(+30\\% / - 10\\%\\) POS 70%) ARWR: Plozasiran PDUFA for FCS (genetic+clinical) 11/18/25 (stock \\(+15\\% / - 20\\%\\) POS 80%) ARWR: ARO-INHBE ph.II/II interim data in adults w/ obesity 4Q25 (stock \\(+30\\% / - 15\\%\\) POS 55%) ARWR: ARO-DUX4/DM1 interim look for DM1 and DUX4 FSHD data and milestone payments 4Q25 (stock \\(+10\\% / - 5\\%\\) POS 70%) BCRX: Orladeyo PDUFA for pediatric (2- 11yo) HAE oral prophy (12/12/25) (stock \\(+10\\% / - 5\\%\\) POS 80%) BCRX: BCX17725 ph.I Netherton initial data YE25 (stock \\(+15\\% / - 5\\%\\) POS 60%) BCRX: Avarolstat ph.I DME initial data YE25 (stock \\(+15\\% / - 5\\%\\) POS 50%) BDTX: BDTX- 1535 ph.II 1L data in non- classical EGFRm NSCLC pts 4Q25 (stock \\(+100\\% / - 50\\%\\) POS 70%) CELC: Detailed presentation for ph.III WT 2L aBC at a medical meeting (est SABCS) 4Q25 (stock \\(+ / - 20\\%\\) POS 50%) CELC: Ph.III top- line data in PIK3CA mutant (MT) 2L aBC 4Q25 (stock \\(+40\\% / - 20\\%\\) POS 60%) CELC: Detailed presentation for ph.IB/II mCRPC @ESMO (stock \\(+ / - 10\\%\\) POS 20%) CMPX: PFS/OS/Dor data from CTX- 009 ph.II/III 2L BTC study 1Q26 (stock \\(+80\\% / - 50\\%\\) POS 75%) CMPX: CTX- 8371 detail ph.I dose escalation data at a med conf 4Q25 (stock \\(+20\\% / - 10\\%\\) POS 75%) CRBP: Completion of CRB- 701 ph.I dose optimization and data report @ESMO (stock \\(+50\\% / - 30\\%\\) POS 60%) CRBP: CRB- 701 dose optimization data from partner CSPC 2H25/1H26 (stock \\(+30\\% / - 10\\%\\) POS 45%) CRBP: CRB- 913 (obesity) SAD/MAD safety data in healthy volunteers 2H25 (stock \\(+ / - 30\\%\\) POS 50%) CRDF: Mature PFS data for ph.II 1L CRC and FDA feedback on ph.III design 1Q26 (stock \\(+80\\% / - 70\\%\\) POS 30%) CRSP: CTX112 CAR- T ph.II/II data update for oncology (LBCL) and initial AID data (SLE, SSC, IIM) 2H25 (stock \\(+20\\% / - 30\\%\\) POS 55%) CRSP: CTX131 ph.II/II RCC and TCL data 2H25 (stock \\(+ / - 15\\%\\) POS 50%) CRSP: VCTX211 regenerative medicine platform ph.II/II T1D first look at data 2H25 (stock \\(+ / - 20\\%\\) POS 40%) DNTH: Readthrough from ANNX's oral active C1s inhibitor ANX1502 in CAD POC study (n- 7) based on potential selection of neuromuscular indications YE25 (stock \\(+ / - 10\\%\\) POS for DNTH 85%) DNTH: DNTH103 ph.II safety+efficacy (MG- ADL, QMG) top- line in gMG est mid- Sept'25 (stock \\(+100\\% / - 70\\%\\) POS 80%) ELVN: Readthrough from larger CML ph.I update w/ TERN- 701 4Q25 (stock \\(+ / - 10\\%\\) POS for ELVN 80%) GBIO: Potential outcome of strategic alternatives (stock \\(+50\\% / - 30\\%\\) POS 70%)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "55d9ef2f1fc70fe4",
      "text": "- HOWL: Ph.I/Ib '124 (IL-2) interim monotx and combo w/ pembro expansion cohort data in RCC and Melanoma in 4Q25 (stock >+100%/-30%, POS 50%)- IDYA: Clinical updates of IDE849/SHR-4849 DLL3-ADC ph.I SCLC study in China @WCLC (9/7/25) (stock +20%/-10%, POS 70%)- IDYA: Multiple clinical data updates at R&D Day incl DLL3 ADC data in SCLC @WCLC, neoadjuvant ph.I update, initial MAT2A+Trodelvy data in UC (9/8/25) (stock +15%/-5%, POS 80%)- IDYA: Longer-term follow up from ph.I neoadjuvant UM data (n>90) w/ visual endpts/outcomes data @ESMO (10/20/25) (stock +25%/-5%, POS 75%)- IDYA: mOS data from 1L MUM ph.II (n>40) @Society for Melanoma Research Oct 25-28 to derisk confirmatory OS (stock +/-25%, POS 75%)- IDYA: HLA-A2(-) MUM pivotal mPFS readout for potI accelerated approval path YE25 (stock +50%/-40%, POS 80%)- KALV: Readthrough from PHVS deucritibant HAE oral on-demand ph.II (RAPIDe-3) 4Q25 (stock +35%/-15%, POS 60% for KALV, based on PHVS failure)- KZR: Regulatory update for alignment on AIH pivotal 4Q25 (stock +50%/-25%, POS 70%)- MREO: Ph.III ORBIT final analysis (all pts @18mos) in OI YE25 (stock +100%/-70%, POS >70%)- MRUS: Petosemtamab readthrough from 1st look at OrigAMI-4 ph.I/II data w/ amivantamab monotx in 2L HNSCC @ESMO (10/19/25) (stock +5%/-10%, POS for MRUS 70%)- MRUS: Initial ORR+ safety data w/ peto+/-chemo combo in WT RAS/RAF CRC likely w/ robust 2L cohort and potI 1L/3L+ cohorts (est ESMO Asia) 2H25 (stock +30%/-20%, POS 70%)- NTLA: Lonvo-z (NTLA-2002) longer-term HAE ph.I & ph.II data 2H25 (stock +30%/-10%, POS 70%)- NTLA: Nex-z (NTLA-2001) longer-term ATTR ph.I & ph.II data 2H25 (stock +15%/-10%, POS 70%)- OPK: MDX2201 ph.I EBV vaccine safety+immunogenicity data and potential ph.II go from MRK 3Q25 (stock +/-10%, POS 65%)- OPK: MDX2001 qualitative dose escalation safety data in solid tumors (lung, breast, prostate, pancreatic) 2H25 (stock +/-5%, POS 55%)- ORIC: AddI dose escalation cohorts for '944 +apalutamide and +darolutamide in mCRPC 2H25 (stock +30%/-10%, POS 75%)- ORIC: ORIC-114 NSCLC 1L/2L EGFR exon 20, 2L+ EGFR-atypical and HER2 exon20 data 2H25 (stock +30%/-15%, POS 60%)- PYXS: Ph.I/II MICVO pembro combo in 1/2L+ HNSCC data 2H25 (stock +100%/-50%, POS 50%)- PYXS: Ph.I MICVO mono in 2/3L platinum & PD-1 experienced HNSCC data 2H25 (stock +100%/-50%, POS 50%)- RARE: Ph.III ORBIT final analysis (all pts @18mos; p70%)- RIGL: R289 ph.Ib updated dose escalation data in LR-MDS (est ASH) YE:25 (stock +/- 30%, POS 60%)- RZLT: Topline from RZ358 pivotal ph.III congenital hyperinsulinism Dec'25 (stock +100%/-75%, POS 80%)- SGMO: Fabry BD deal est 4Q25 (stock +100%/-75%, POS 60%)- SGMO: Detailed Fabry topline data @ICIEM2025 (Sept 2-6; stock +20%/-10%, POS 75%)- SLDB: SGT-003 ph.I/II D90 data from 10-12 pts (dosing by Apr'25) and feedback from FDA & EMA on pivotal path 4Q25 (stock +35%/-20%, POS 65%)- TNGX: TNG462 ph.I expansion data in PDAC and NSCLC with durability and plan for 2L PDAC pivotal 2H25 (est 4Q25; stock +75%/-50%, POS 75%)- TNGX: TNG260 pembro combo data in tumors w/ STK11 loss-of-function mutation @med conf 2H25 (stock +30%/-10%, POS 40%)",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "0728c4b9b4ae4534",
      "text": "- TSHA: TSHA-102 Potential opt-in decision by Astellas for Rett syndrome gene therapy est Sept'25 (stock +100%/-30%)- TSHA: TSHA-102 update at med conf 4Q25 (est Child Neurology Society Oct 8-11: stock +30%/-10%; POS 80%)- TSHA: Readthrough from add'l interim ph.I/II Rett data from NGNE's NGN-401 2H25 (stock +/-30%; POS 75% for TSHA)- TVTX: Advisory committee meeting ahead of Filsipari FSGS PDUFA likely 4Q25 (stock +/-30%; POS 70%)- TVTX: Filsipari approval for FSGS (1/13/2026) (stock +75%/-30%; POS 70%)- VALN: Full randomized, controlled immunogenicity+safety data from ph.I for Zika 2H25 (stock +20%/-5%; POS 60%)- VALN: S4V2 infant ph.II safety+immunogenicity data 2H25 (stock +/-10%; POS 60%)- VALN: Topline from VLA15 Lyme ph.III w/ partner PFE YE25 (stock +35%/-25%; POS 75%)- VERA: Readthroughs from Otsuka's sibeprenilimab IgAN approval and label 11/28/25 (stock +30%/-15%; POS 60%)",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "11be6078752426b8",
      "text": "- American Academy of Pediatrics (AAP; Sept 26-30): program here- European Respiratory Society (ERS; Sept 27-Oct 1): regular & LBA titles here; abstracts post 2wks before congress (except embargoed abstracts)- American Society for Radiation Oncology (ASTRO; Sept 27-Oct 1)- AACR Special Conference in Cancer Research - Advances in Pancreatic Cancer Research (Sept 28-Oct 1): program here; titles+abstracts post 1st day of meeting- United European Gastroenterology Week (UEGW; Oct 4-7): program here- European Association of Nuclear Medicine (EANM; Oct 4-8): program here- Cell & Gene Meeting on the Mesa (Oct 6-8): program here- European Society of Gene & Cell Therapy (ESGCT; Oct 7-10): program here; abstracts post Oct 1 @5AM ET- International Congress of the World Muscle Society (WMS; Oct 7-11); program & regular titles here; LBA titles Sept 22; regular+LBA abstracts post Sept 30 to attendees- Child Neurology Society (CNS, Oct 8-11): program here; abstracts post on 1st day of meeting- Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI; Oct 9-12): program here- European School of Haematology Annual Conference on Chronic Myeloid Leukemia (ESH- iCMLf; Oct 10-12): program here- HAEi Regional Conference EMEA (Oct 10-12)- American Society of Human Genetics (ASHG; Oct 14-18): program here- European Association of Neuro-Oncology (EANO; Oct 16-19): program here; abstracts post Oct 2- European Society for Medical Oncology (ESMO; Oct 17-21): program & regular titles here; LBA titles by Sept 20; regular abstracts post Oct 12 @6:05PM ET; LBA abstracts post on day of presentation- American Academy of Ophthalmology (AAO; Oct 18-20): program here; titles & abstracts post Sept 2- Oligonucleotide Therapeutics Society (OTS; Oct 19-22): program here; short talk titles post early- Sept; poster titles post 3rd wk of Sept; abstracts post by Oct 7- North American Cystic Fibrosis Conference (NACFC; Oct 22-25): program here; titles & abstracts post online Oct 1 in the Journal of Cystic Fibrosis- EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics (Oct 22-26): program here; regular & LBA titles will post Oct 13 @12PM ET; abstracts will post Oct 22 @12PM ET (except embargoed)- American College of Gastroenterology (ACG; Oct 24-29): program here; regular titles & abstracts post 1st wk of Sept; LBA titles & abstracts post early- Oct (embargo lift Oct 26 @2PM ET)- American College of Rheumatology (ACR; Oct 24-29): program here; regular titles & abstracts post early- Sept; LBA titles & abstracts post early- Oct (embargo lift Oct 25 @11AM ET)- Society for Melanoma Research (SMR; Oct 25-28): program here; LBA oral titles post the week of Sept 29; abstracts available to registered attendees only; IDYA will have an oral presentation (#209) for first mOS data from ph.I/II 1L MUM in >40 pts (OptimUM-01)- World Orphan Drug Congress (Oct 27-29): program here; titles post 2-3wks before event; abstracts are not made available- American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM; Oct 29-Nov 1): program here; abstracts post Sept 15- Obesity week (Nov 4-7): Program here; abstracts post on Nov 4 @12PM ET",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "697a3b98b649cf53",
      "text": "International Gynecologic Cancer Society (IGCS; Nov 5- 7): program & regular titles here; regular abstracts post Oct 15; LBA titles post Oct 29; LBA abstracts post on day of presentation Society for Immunotherapy of Cancer (SITC; Nov 5- 9): program here; reg titles post Oct 3 @9AM ET; LBA titles post Oct 30 @9AM ET; reg abstracts post Nov 4 @9AM ET; LBA abstracts post Nov 7 @9AM ET American Society of Nephrology (ASN; Nov 6- 9): program here; titles & regular abstracts post Oct 17; LBA abstracts are embargoed until time of presentation American College of Allergy, Asthma & Immunology (ACAAI, Nov 6- 10): program here; regular title post early- Sept; LBA titles post mid- Oct; regular & LBA abstracts post Nov 6 @8AM ET FAST Global Science Summit & Gala (Angelman; Nov 7- 8): program here American Heart Association (AHA; Nov 7- 10): program here; abstract acceptance notice by mid- Sept; embargo lift at time of presentation American Association for the Study of Liver Diseases (AASLD; Nov 7- 11): program here; regular titles & abstracts post Oct 7 @8AM ET; LBA titles & abstracts post Nov 7 @8AM ET Connective Tissue Oncology Society (CTOS; Nov 12- 15): program here Society for Neuro- Oncology (SNO) & World Federation of Neuro- Oncology Societies (WFNOS) (Nov 19- 23): program here; regular titles post by mid- Sept; regular abstracts post on Nov 10 @7AM ET; LBA titles+abstracts post on day of presentation International Congress on Neuromuscular Diseases (ICNMDigital, Nov 20- 21): program here ESMO Asia (Dec 5- 7): program here; regular titles will post early- Oct; LBA titles post by end- Oct",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "a53f1dd68010fd2a",
      "text": "- ALNY: Amvutta Weekly \"Sales Tracker\": ATTR-CM Sales Strong Half-Way Through 3Q- VALN: FDA Suspends BLA for Ixchiq; U.S. Path Is Unclear At This Point",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "17287c60d5432467",
      "text": "(Article 3(1)e and Article 7 of MAR) Recommendation Published Recommendation Distributed",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "4f8953ef4626ebee",
      "text": "August 31, 2025 19:40 P.M. August 31, 2025 19:40 P.M.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "3eab2067ab0058be",
      "text": "Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(10\\) is \\(20\\%\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is plus or minus \\(20\\%\\) within a 12- month period. For Underperform rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is minus \\(20\\%\\) or less within a 12- month period. NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "fe0c4473c696abf1",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "27da0fc298981a36",
      "text": "NC - Not covered. Jefferies does not cover this company.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "2e1cf07b96767c5d",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "067c4f914711c12a",
      "text": "Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "0e8928b0e54155fc",
      "text": "Jefferies methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "4d3fd96f0d036d66",
      "text": "Jefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "3907cbc6672075e8",
      "text": "desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "e7077b9c0a0ea61a",
      "text": "Jefferies does busines and seeks to do busines with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "c87a0b601fd7bcb9",
      "text": "Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Financial Group Inc. (Jefferies) companies: United States: Jefferies LLC which is an SEC registered broker- dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "816907313d2e6a5e",
      "text": "Canada: Jefferies Securities Inc., which is an investment dealer registered in each of the thirteen Canadian jurisdictions and a dealer member of the Canadian Investment Regulatory Organization, including research reports produced jointly by Jefferies Securities Inc. and another Jefferies entity (and distributed by Jefferies Securities Inc.).",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "b220854711acad4c",
      "text": "Where Jefferies Securities Inc. distributes research reports produced by Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch or Jefferies India Private Limited, you are advised that each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited operates as a dealer in your jurisdiction under an exemption from the dealer registration requirements contained in National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and, as such, each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited is not required to be and is not a registered dealer or adviser in your jurisdiction. You are advised that where Jefferies LLC or Jefferies International Limited prepared this research report, it was not prepared in accordance with Canadian disclosure requirements relating to research reports in Canada.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "9302047f2ab61e2f",
      "text": "United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority, registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "70f1aa92cac05499",
      "text": "Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1- 1- 2 Yurakucho, Chiyoda- ku, Tokyo 100- 0006; telephone +813 5251 6100; facsimile +813 5251 6101.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "5cea4db2141e1e9e",
      "text": "Australia: Jefferies (Australia) Pty Limited (ACN 623 059 898), which holds an Australian financial services license (AFSL 504712) and is located at Level 20, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "ec9954515353cc4c",
      "text": "Dubai: Jefferies International Limited, Dubai branch, which is licensed by the Dubai Financial Services Authority (DFSA Reference Number F007325); registered office Unit L31- 06, L31- 07, Level 31, ICD Brookfield Pace, DIFC, PO Box 121208, Dubai, UAE.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "e4f69410aa191c50",
      "text": "This report was prepared by personnel who are associated with Jefferies (Jefferies Securities Inc., Jefferies International Limited, Jefferies GmbH, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), and Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC (\"JRS\"). Jefferies LLC is a US registered broker- dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as \"Jefferies\". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA, the Canadian Investment Regulatory Organization and other rules are set forth in this disclosure section.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "177462aa83828ffe",
      "text": "If you are receiving this report from a non- US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a- 6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited (\"JIL\") and/or Jefferies GmbH and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies LLC, JIL, Jefferies GmbH and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under \"company specific disclosures\".",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "9f92c959ee9ecbe8",
      "text": "For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a permitted client as defined by National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations, as applicable. This research report is a general discussion of the merits and risks of a security or securities only, and is not in any way meant to be tailored to the needs and circumstances of any recipient. The information contained herein is not, and under no circumstances is to be construed as, an offer to sell securities described herein, or solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators, if applicable, and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed judgment upon this research report, the information contained herein or the merits of the securities described herein, and any representation to the contrary is an offence.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "9c53b48149a4ecb4",
      "text": "By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker-dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker- dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser, and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "0df40ce78b62e0ac",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "38355c02497c0a12",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "fea02373cf42be18",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "b06140b87f97b112",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third-party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third-party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third-party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "87b9adaccc528924",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "e5415b2c287d41d8",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/IAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888.JEFFERIES.",
      "page": 11,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "b328caac9f727678",
      "name": "AACR International",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "27bd900f6b5dd2fa",
      "name": "AACR Special",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4cb5053d0e26a465",
      "name": "ASND TransCon",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "867a9dfe274a629d",
      "name": "American Academy",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7c2bb15fd7643a53",
      "name": "American Association",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "38efa2e9cded7911",
      "name": "American College",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "756f35f2e04b7108",
      "name": "American Heart",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cbf19603e95d6dfd",
      "name": "American Society",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7be9f80639ba63d4",
      "name": "Amvutta Weekly",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2ebc1f6a39f03ec8",
      "name": "Asia Pacific",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8eaa094f57327b3b",
      "name": "Biotechnology\n\nWeek",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4ca33450523f37c3",
      "name": "CM Sales",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7b1b4acf827ee493",
      "name": "CNP Achondroplasia",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "239dec50a197cf8c",
      "name": "Cancer Research",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9e195538e7b842c5",
      "name": "Cancer Therapeutics",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "1f9780e6c7676c1f",
      "name": "Cell Therapy",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "fd3ae82611f969b9",
      "name": "Child Neurology",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "533a5308f4bf444e",
      "name": "Chronic Myeloid",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "66690ec987a39a52",
      "name": "Clinical Immunology",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "260b8f7b7c376bf9",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "R: Readthroughs from IONS' pivotal CORE/CORE2 data in SHTG in Sept'25 (stock \\(+30\\% / - 10\\%\\) POS 70%) ARWR: Plozasiran PDUFA for FCS (genetic+clinical) 11/18/25 (stock \\(+15\\% / - 20\\%\\) POS 80%) A",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "2798e51642aa6475",
        "value": 0.8,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ") POS 70%) ARWR: Plozasiran PDUFA for FCS (genetic+clinical) 11/18/25 (stock \\(+15\\% / - 20\\%\\) POS 80%) ARWR: ARO-INHBE ph.II/II interim data in adults w/ obesity 4Q25 (stock \\(+30\\% / - 15\\%\\) POS 5",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "cfce6a9d157acb0a",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "80%) ARWR: ARO-INHBE ph.II/II interim data in adults w/ obesity 4Q25 (stock \\(+30\\% / - 15\\%\\) POS 55%) ARWR: ARO-DUX4/DM1 interim look for DM1 and DUX4 FSHD data and milestone payments 4Q25 (stock \\(",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "1467f65a9785421f",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "M1 interim look for DM1 and DUX4 FSHD data and milestone payments 4Q25 (stock \\(+10\\% / - 5\\%\\) POS 70%) BCRX: Orladeyo PDUFA for pediatric (2- 11yo) HAE oral prophy (12/12/25) (stock \\(+10\\% / - 5\\%\\",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "5cbd92f51aadf1e3",
        "value": 0.8,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "CRX: Orladeyo PDUFA for pediatric (2- 11yo) HAE oral prophy (12/12/25) (stock \\(+10\\% / - 5\\%\\) POS 80%) BCRX: BCX17725 ph.I Netherton initial data YE25 (stock \\(+15\\% / - 5\\%\\) POS 60%) BCRX: Avarols",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "572b3107e742d924",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0\\% / - 5\\%\\) POS 80%) BCRX: BCX17725 ph.I Netherton initial data YE25 (stock \\(+15\\% / - 5\\%\\) POS 60%) BCRX: Avarolstat ph.I DME initial data YE25 (stock \\(+15\\% / - 5\\%\\) POS 50%) BDTX: BDTX- 1535 ",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "fb12eece47f9440f",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "\\(+15\\% / - 5\\%\\) POS 60%) BCRX: Avarolstat ph.I DME initial data YE25 (stock \\(+15\\% / - 5\\%\\) POS 50%) BDTX: BDTX- 1535 ph.II 1L data in non- classical EGFRm NSCLC pts 4Q25 (stock \\(+100\\% / - 50\\%\\",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "cead749c6cdcce5f",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "DTX: BDTX- 1535 ph.II 1L data in non- classical EGFRm NSCLC pts 4Q25 (stock \\(+100\\% / - 50\\%\\) POS 70%) CELC: Detailed presentation for ph.III WT 2L aBC at a medical meeting (est SABCS) 4Q25 (stock \\",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "f558c3f8f936688a",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d presentation for ph.III WT 2L aBC at a medical meeting (est SABCS) 4Q25 (stock \\(+ / - 20\\%\\) POS 50%) CELC: Ph.III top- line data in PIK3CA mutant (MT) 2L aBC 4Q25 (stock \\(+40\\% / - 20\\%\\) POS 60%",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "b713c869f5c0d640",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "OS 50%) CELC: Ph.III top- line data in PIK3CA mutant (MT) 2L aBC 4Q25 (stock \\(+40\\% / - 20\\%\\) POS 60%) CELC: Detailed presentation for ph.IB/II mCRPC @ESMO (stock \\(+ / - 10\\%\\) POS 20%) CMPX: PFS/O",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "103e3a19fb1a4afa",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/ - 20\\%\\) POS 60%) CELC: Detailed presentation for ph.IB/II mCRPC @ESMO (stock \\(+ / - 10\\%\\) POS 20%) CMPX: PFS/OS/Dor data from CTX- 009 ph.II/III 2L BTC study 1Q26 (stock \\(+80\\% / - 50\\%\\) POS 75",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "10990b61396350ad",
        "value": 0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "20%) CMPX: PFS/OS/Dor data from CTX- 009 ph.II/III 2L BTC study 1Q26 (stock \\(+80\\% / - 50\\%\\) POS 75%) CMPX: CTX- 8371 detail ph.I dose escalation data at a med conf 4Q25 (stock \\(+20\\% / - 10\\%\\) PO",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "6223fc82c540466b",
        "value": 0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ") CMPX: CTX- 8371 detail ph.I dose escalation data at a med conf 4Q25 (stock \\(+20\\% / - 10\\%\\) POS 75%) CRBP: Completion of CRB- 701 ph.I dose optimization and data report @ESMO (stock \\(+50\\% / - 30",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "d7b0ee07b8e2f44b",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ": Completion of CRB- 701 ph.I dose optimization and data report @ESMO (stock \\(+50\\% / - 30\\%\\) POS 60%) CRBP: CRB- 701 dose optimization data from partner CSPC 2H25/1H26 (stock \\(+30\\% / - 10\\%\\) POS",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "0e851767f7f2f12f",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0%) CRBP: CRB- 701 dose optimization data from partner CSPC 2H25/1H26 (stock \\(+30\\% / - 10\\%\\) POS 45%) CRBP: CRB- 913 (obesity) SAD/MAD safety data in healthy volunteers 2H25 (stock \\(+ / - 30\\%\\) P",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "3936f4a3283538d9",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ") CRBP: CRB- 913 (obesity) SAD/MAD safety data in healthy volunteers 2H25 (stock \\(+ / - 30\\%\\) POS 50%) CRDF: Mature PFS data for ph.II 1L CRC and FDA feedback on ph.III design 1Q26 (stock \\(+80\\% / ",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "dc11ca87fa4c8fb3",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ture PFS data for ph.II 1L CRC and FDA feedback on ph.III design 1Q26 (stock \\(+80\\% / - 70\\%\\) POS 30%) CRSP: CTX112 CAR- T ph.II/II data update for oncology (LBCL) and initial AID data (SLE, SSC, II",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "84faad887c4933c2",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "update for oncology (LBCL) and initial AID data (SLE, SSC, IIM) 2H25 (stock \\(+20\\% / - 30\\%\\) POS 55%) CRSP: CTX131 ph.II/II RCC and TCL data 2H25 (stock \\(+ / - 15\\%\\) POS 50%) CRSP: VCTX211 regener",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "3941c8255b1ec13c",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "k \\(+20\\% / - 30\\%\\) POS 55%) CRSP: CTX131 ph.II/II RCC and TCL data 2H25 (stock \\(+ / - 15\\%\\) POS 50%) CRSP: VCTX211 regenerative medicine platform ph.II/II T1D first look at data 2H25 (stock \\(+ / ",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "023b16fb656c10c0",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "TX211 regenerative medicine platform ph.II/II T1D first look at data 2H25 (stock \\(+ / - 20\\%\\) POS 40%) DNTH: Readthrough from ANNX's oral active C1s inhibitor ANX1502 in CAD POC study (n- 7) based o",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "bca681282c5b8e62",
        "value": 0.85,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ") based on potential selection of neuromuscular indications YE25 (stock \\(+ / - 10\\%\\) POS for DNTH 85%) DNTH: DNTH103 ph.II safety+efficacy (MG- ADL, QMG) top- line in gMG est mid- Sept'25 (stock \\(+",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "fe6c37a9a44ba5fe",
        "value": 0.8,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".II safety+efficacy (MG- ADL, QMG) top- line in gMG est mid- Sept'25 (stock \\(+100\\% / - 70\\%\\) POS 80%) ELVN: Readthrough from larger CML ph.I update w/ TERN- 701 4Q25 (stock \\(+ / - 10\\%\\) POS for E",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "5783c9b2517dd380",
        "value": 0.8,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ELVN: Readthrough from larger CML ph.I update w/ TERN- 701 4Q25 (stock \\(+ / - 10\\%\\) POS for ELVN 80%) GBIO: Potential outcome of strategic alternatives (stock \\(+50\\% / - 30\\%\\) POS 70%)<｜end▁of▁sen",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "d02bc5fb374b2a74",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ") POS for ELVN 80%) GBIO: Potential outcome of strategic alternatives (stock \\(+50\\% / - 30\\%\\) POS 70%)<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "e2bb1c226399338f",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(IL-2) interim monotx and combo w/ pembro expansion cohort data in RCC and Melanoma in 4Q25 (stock >+100%/-30%, POS 50%)- IDYA: Clinical updates of IDE849/SHR-4849 DLL3-ADC ph.I SCLC study in China @W",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ed72a804131840ce",
        "value": -0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "interim monotx and combo w/ pembro expansion cohort data in RCC and Melanoma in 4Q25 (stock >+100%/-30%, POS 50%)- IDYA: Clinical updates of IDE849/SHR-4849 DLL3-ADC ph.I SCLC study in China @WCLC (9/",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "96e55bbc4ee0af88",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "onotx and combo w/ pembro expansion cohort data in RCC and Melanoma in 4Q25 (stock >+100%/-30%, POS 50%)- IDYA: Clinical updates of IDE849/SHR-4849 DLL3-ADC ph.I SCLC study in China @WCLC (9/7/25) (st",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "239f24b108aa4376",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "- IDYA: Clinical updates of IDE849/SHR-4849 DLL3-ADC ph.I SCLC study in China @WCLC (9/7/25) (stock +20%/-10%, POS 70%)- IDYA: Multiple clinical data updates at R&D Day incl DLL3 ADC data in SCLC @WCL",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "4446827054b6c4f8",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "A: Clinical updates of IDE849/SHR-4849 DLL3-ADC ph.I SCLC study in China @WCLC (9/7/25) (stock +20%/-10%, POS 70%)- IDYA: Multiple clinical data updates at R&D Day incl DLL3 ADC data in SCLC @WCLC, ne",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "db44b64565626193",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "l updates of IDE849/SHR-4849 DLL3-ADC ph.I SCLC study in China @WCLC (9/7/25) (stock +20%/-10%, POS 70%)- IDYA: Multiple clinical data updates at R&D Day incl DLL3 ADC data in SCLC @WCLC, neoadjuvant ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "1577b65643fa0c51",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ADC data in SCLC @WCLC, neoadjuvant ph.I update, initial MAT2A+Trodelvy data in UC (9/8/25) (stock +15%/-5%, POS 80%)- IDYA: Longer-term follow up from ph.I neoadjuvant UM data (n>90) w/ visual endpts",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "35139f336981dbfb",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "data in SCLC @WCLC, neoadjuvant ph.I update, initial MAT2A+Trodelvy data in UC (9/8/25) (stock +15%/-5%, POS 80%)- IDYA: Longer-term follow up from ph.I neoadjuvant UM data (n>90) w/ visual endpts/out",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a5facd561c8c5aa7",
        "value": 0.8,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "CLC @WCLC, neoadjuvant ph.I update, initial MAT2A+Trodelvy data in UC (9/8/25) (stock +15%/-5%, POS 80%)- IDYA: Longer-term follow up from ph.I neoadjuvant UM data (n>90) w/ visual endpts/outcomes dat",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9019a3c67c2b861a",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "llow up from ph.I neoadjuvant UM data (n>90) w/ visual endpts/outcomes data @ESMO (10/20/25) (stock +25%/-5%, POS 75%)- IDYA: mOS data from 1L MUM ph.II (n>40) @Society for Melanoma Research Oct 25-28",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "aa56bbdc0bb493d3",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "up from ph.I neoadjuvant UM data (n>90) w/ visual endpts/outcomes data @ESMO (10/20/25) (stock +25%/-5%, POS 75%)- IDYA: mOS data from 1L MUM ph.II (n>40) @Society for Melanoma Research Oct 25-28 to d",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "865a7566bc8c73b2",
        "value": 0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "h.I neoadjuvant UM data (n>90) w/ visual endpts/outcomes data @ESMO (10/20/25) (stock +25%/-5%, POS 75%)- IDYA: mOS data from 1L MUM ph.II (n>40) @Society for Melanoma Research Oct 25-28 to derisk con",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "4f13cb3f24a20500",
        "value": -0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rom 1L MUM ph.II (n>40) @Society for Melanoma Research Oct 25-28 to derisk confirmatory OS (stock +/-25%, POS 75%)- IDYA: HLA-A2(-) MUM pivotal mPFS readout for potI accelerated approval path YE25 (st",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "57cdcf1f2366659a",
        "value": 0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ph.II (n>40) @Society for Melanoma Research Oct 25-28 to derisk confirmatory OS (stock +/-25%, POS 75%)- IDYA: HLA-A2(-) MUM pivotal mPFS readout for potI accelerated approval path YE25 (stock +50%/-4",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9e0bea1b56207eaa",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ", POS 75%)- IDYA: HLA-A2(-) MUM pivotal mPFS readout for potI accelerated approval path YE25 (stock +50%/-40%, POS 80%)- KALV: Readthrough from PHVS deucritibant HAE oral on-demand ph.II (RAPIDe-3) 4Q",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "4c16f56b4c91a5fc",
        "value": -0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "75%)- IDYA: HLA-A2(-) MUM pivotal mPFS readout for potI accelerated approval path YE25 (stock +50%/-40%, POS 80%)- KALV: Readthrough from PHVS deucritibant HAE oral on-demand ph.II (RAPIDe-3) 4Q25 (st",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "89a875b452f2aa33",
        "value": 0.8,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "A: HLA-A2(-) MUM pivotal mPFS readout for potI accelerated approval path YE25 (stock +50%/-40%, POS 80%)- KALV: Readthrough from PHVS deucritibant HAE oral on-demand ph.II (RAPIDe-3) 4Q25 (stock +35%/",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "84f2a1b7f7d31cd2",
        "value": 0.35,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "POS 80%)- KALV: Readthrough from PHVS deucritibant HAE oral on-demand ph.II (RAPIDe-3) 4Q25 (stock +35%/-15%, POS 60% for KALV, based on PHVS failure)- KZR: Regulatory update for alignment on AIH pivo",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "12e75a8123eb7df3",
        "value": -0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "80%)- KALV: Readthrough from PHVS deucritibant HAE oral on-demand ph.II (RAPIDe-3) 4Q25 (stock +35%/-15%, POS 60% for KALV, based on PHVS failure)- KZR: Regulatory update for alignment on AIH pivotal ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "1f968a35e5ef1b55",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ": Readthrough from PHVS deucritibant HAE oral on-demand ph.II (RAPIDe-3) 4Q25 (stock +35%/-15%, POS 60% for KALV, based on PHVS failure)- KZR: Regulatory update for alignment on AIH pivotal 4Q25 (stoc",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "cc81a25393a8f9ff",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "% for KALV, based on PHVS failure)- KZR: Regulatory update for alignment on AIH pivotal 4Q25 (stock +50%/-25%, POS 70%)- MREO: Ph.III ORBIT final analysis (all pts @18mos) in OI YE25 (stock +100%/-70%",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "efdb27ae417de231",
        "value": -0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "KALV, based on PHVS failure)- KZR: Regulatory update for alignment on AIH pivotal 4Q25 (stock +50%/-25%, POS 70%)- MREO: Ph.III ORBIT final analysis (all pts @18mos) in OI YE25 (stock +100%/-70%, POS ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9e5eef2e2861b7e0",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ed on PHVS failure)- KZR: Regulatory update for alignment on AIH pivotal 4Q25 (stock +50%/-25%, POS 70%)- MREO: Ph.III ORBIT final analysis (all pts @18mos) in OI YE25 (stock +100%/-70%, POS >70%)- MR",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "508adca824b3ded4",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "25 (stock +50%/-25%, POS 70%)- MREO: Ph.III ORBIT final analysis (all pts @18mos) in OI YE25 (stock +100%/-70%, POS >70%)- MRUS: Petosemtamab readthrough from 1st look at OrigAMI-4 ph.I/II data w/ ami",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "3c4ec7f044710625",
        "value": -0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ock +50%/-25%, POS 70%)- MREO: Ph.III ORBIT final analysis (all pts @18mos) in OI YE25 (stock +100%/-70%, POS >70%)- MRUS: Petosemtamab readthrough from 1st look at OrigAMI-4 ph.I/II data w/ amivantam",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9ff8b122e11f3bb6",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "5%, POS 70%)- MREO: Ph.III ORBIT final analysis (all pts @18mos) in OI YE25 (stock +100%/-70%, POS >70%)- MRUS: Petosemtamab readthrough from 1st look at OrigAMI-4 ph.I/II data w/ amivantamab monotx i",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "aca576f774a472f2",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "h from 1st look at OrigAMI-4 ph.I/II data w/ amivantamab monotx in 2L HNSCC @ESMO (10/19/25) (stock +5%/-10%, POS for MRUS 70%)- MRUS: Initial ORR+ safety data w/ peto+/-chemo combo in WT RAS/RAF CRC ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "f9c1fbb9ebbd7a0a",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "om 1st look at OrigAMI-4 ph.I/II data w/ amivantamab monotx in 2L HNSCC @ESMO (10/19/25) (stock +5%/-10%, POS for MRUS 70%)- MRUS: Initial ORR+ safety data w/ peto+/-chemo combo in WT RAS/RAF CRC like",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "44c09ebadbb7f6d6",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "AMI-4 ph.I/II data w/ amivantamab monotx in 2L HNSCC @ESMO (10/19/25) (stock +5%/-10%, POS for MRUS 70%)- MRUS: Initial ORR+ safety data w/ peto+/-chemo combo in WT RAS/RAF CRC likely w/ robust 2L coh",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "0e43259a532654d4",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "bo in WT RAS/RAF CRC likely w/ robust 2L cohort and potI 1L/3L+ cohorts (est ESMO Asia) 2H25 (stock +30%/-20%, POS 70%)- NTLA: Lonvo-z (NTLA-2002) longer-term HAE ph.I & ph.II data 2H25 (stock +30%/-1",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "6b46f90b4ba5c22a",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "WT RAS/RAF CRC likely w/ robust 2L cohort and potI 1L/3L+ cohorts (est ESMO Asia) 2H25 (stock +30%/-20%, POS 70%)- NTLA: Lonvo-z (NTLA-2002) longer-term HAE ph.I & ph.II data 2H25 (stock +30%/-10%, PO",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9ce024d719e65c43",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "F CRC likely w/ robust 2L cohort and potI 1L/3L+ cohorts (est ESMO Asia) 2H25 (stock +30%/-20%, POS 70%)- NTLA: Lonvo-z (NTLA-2002) longer-term HAE ph.I & ph.II data 2H25 (stock +30%/-10%, POS 70%)- N",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "5bca87839fc866eb",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(stock +30%/-20%, POS 70%)- NTLA: Lonvo-z (NTLA-2002) longer-term HAE ph.I & ph.II data 2H25 (stock +30%/-10%, POS 70%)- NTLA: Nex-z (NTLA-2001) longer-term ATTR ph.I & ph.II data 2H25 (stock +15%/-10",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "8eb3b101823a42ca",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "k +30%/-20%, POS 70%)- NTLA: Lonvo-z (NTLA-2002) longer-term HAE ph.I & ph.II data 2H25 (stock +30%/-10%, POS 70%)- NTLA: Nex-z (NTLA-2001) longer-term ATTR ph.I & ph.II data 2H25 (stock +15%/-10%, PO",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "4b7375d499901389",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%, POS 70%)- NTLA: Lonvo-z (NTLA-2002) longer-term HAE ph.I & ph.II data 2H25 (stock +30%/-10%, POS 70%)- NTLA: Nex-z (NTLA-2001) longer-term ATTR ph.I & ph.II data 2H25 (stock +15%/-10%, POS 70%)- OP",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "be2019ed4c46370c",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(stock +30%/-10%, POS 70%)- NTLA: Nex-z (NTLA-2001) longer-term ATTR ph.I & ph.II data 2H25 (stock +15%/-10%, POS 70%)- OPK: MDX2201 ph.I EBV vaccine safety+immunogenicity data and potential ph.II go ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "1d85c7f051a6299f",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ck +30%/-10%, POS 70%)- NTLA: Nex-z (NTLA-2001) longer-term ATTR ph.I & ph.II data 2H25 (stock +15%/-10%, POS 70%)- OPK: MDX2201 ph.I EBV vaccine safety+immunogenicity data and potential ph.II go from",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "120aef5ce8feeb85",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0%, POS 70%)- NTLA: Nex-z (NTLA-2001) longer-term ATTR ph.I & ph.II data 2H25 (stock +15%/-10%, POS 70%)- OPK: MDX2201 ph.I EBV vaccine safety+immunogenicity data and potential ph.II go from MRK 3Q25 ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "670a213c279c46e2",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ": MDX2201 ph.I EBV vaccine safety+immunogenicity data and potential ph.II go from MRK 3Q25 (stock +/-10%, POS 65%)- OPK: MDX2001 qualitative dose escalation safety data in solid tumors (lung, breast, ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "2ebe401abb9b9fe7",
        "value": 0.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ph.I EBV vaccine safety+immunogenicity data and potential ph.II go from MRK 3Q25 (stock +/-10%, POS 65%)- OPK: MDX2001 qualitative dose escalation safety data in solid tumors (lung, breast, prostate, ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "184eb648032b7812",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tive dose escalation safety data in solid tumors (lung, breast, prostate, pancreatic) 2H25 (stock +/-5%, POS 55%)- ORIC: AddI dose escalation cohorts for '944 +apalutamide and +darolutamide in mCRPC 2",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b3807681017ccb2c",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "escalation safety data in solid tumors (lung, breast, prostate, pancreatic) 2H25 (stock +/-5%, POS 55%)- ORIC: AddI dose escalation cohorts for '944 +apalutamide and +darolutamide in mCRPC 2H25 (stock",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c28e296eb190d093",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%)- ORIC: AddI dose escalation cohorts for '944 +apalutamide and +darolutamide in mCRPC 2H25 (stock +30%/-10%, POS 75%)- ORIC: ORIC-114 NSCLC 1L/2L EGFR exon 20, 2L+ EGFR-atypical and HER2 exon20 data",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "7b7f3e1cb3bdae08",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "RIC: AddI dose escalation cohorts for '944 +apalutamide and +darolutamide in mCRPC 2H25 (stock +30%/-10%, POS 75%)- ORIC: ORIC-114 NSCLC 1L/2L EGFR exon 20, 2L+ EGFR-atypical and HER2 exon20 data 2H25",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9800941a972fdddd",
        "value": 0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "dose escalation cohorts for '944 +apalutamide and +darolutamide in mCRPC 2H25 (stock +30%/-10%, POS 75%)- ORIC: ORIC-114 NSCLC 1L/2L EGFR exon 20, 2L+ EGFR-atypical and HER2 exon20 data 2H25 (stock +3",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "e536dc48a2fa37eb",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "S 75%)- ORIC: ORIC-114 NSCLC 1L/2L EGFR exon 20, 2L+ EGFR-atypical and HER2 exon20 data 2H25 (stock +30%/-15%, POS 60%)- PYXS: Ph.I/II MICVO pembro combo in 1/2L+ HNSCC data 2H25 (stock +100%/-50%, PO",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "4b091982168de8d6",
        "value": -0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")- ORIC: ORIC-114 NSCLC 1L/2L EGFR exon 20, 2L+ EGFR-atypical and HER2 exon20 data 2H25 (stock +30%/-15%, POS 60%)- PYXS: Ph.I/II MICVO pembro combo in 1/2L+ HNSCC data 2H25 (stock +100%/-50%, POS 50%",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b448a3d26e87d301",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "RIC-114 NSCLC 1L/2L EGFR exon 20, 2L+ EGFR-atypical and HER2 exon20 data 2H25 (stock +30%/-15%, POS 60%)- PYXS: Ph.I/II MICVO pembro combo in 1/2L+ HNSCC data 2H25 (stock +100%/-50%, POS 50%)- PYXS: P",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a3c2cbfbb2c58572",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "a 2H25 (stock +30%/-15%, POS 60%)- PYXS: Ph.I/II MICVO pembro combo in 1/2L+ HNSCC data 2H25 (stock +100%/-50%, POS 50%)- PYXS: Ph.I MICVO mono in 2/3L platinum & PD-1 experienced HNSCC data 2H25 (sto",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "27c63079648db085",
        "value": -0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(stock +30%/-15%, POS 60%)- PYXS: Ph.I/II MICVO pembro combo in 1/2L+ HNSCC data 2H25 (stock +100%/-50%, POS 50%)- PYXS: Ph.I MICVO mono in 2/3L platinum & PD-1 experienced HNSCC data 2H25 (stock +100",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a4ae5332bc69a52f",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "A: TSHA-102 Potential opt-in decision by Astellas for Rett syndrome gene therapy est Sept'25 (stock +100%/-30%)- TSHA: TSHA-102 update at med conf 4Q25 (est Child Neurology Society Oct 8-11: stock +30",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "923ab7e2049cc7a9",
        "value": -0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "A-102 Potential opt-in decision by Astellas for Rett syndrome gene therapy est Sept'25 (stock +100%/-30%)- TSHA: TSHA-102 update at med conf 4Q25 (est Child Neurology Society Oct 8-11: stock +30%/-10%",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "1d5c0bcaf02de351",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ck +100%/-30%)- TSHA: TSHA-102 update at med conf 4Q25 (est Child Neurology Society Oct 8-11: stock +30%/-10%; POS 80%)- TSHA: Readthrough from add'l interim ph.I/II Rett data from NGNE's NGN-401 2H25",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "0d5bc970aef9bf8b",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "00%/-30%)- TSHA: TSHA-102 update at med conf 4Q25 (est Child Neurology Society Oct 8-11: stock +30%/-10%; POS 80%)- TSHA: Readthrough from add'l interim ph.I/II Rett data from NGNE's NGN-401 2H25 (sto",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "66d749d7f0a68c2d",
        "value": 0.8,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "TSHA: TSHA-102 update at med conf 4Q25 (est Child Neurology Society Oct 8-11: stock +30%/-10%; POS 80%)- TSHA: Readthrough from add'l interim ph.I/II Rett data from NGNE's NGN-401 2H25 (stock +/-30%; ",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "4d5036463bee1d3d",
        "value": -0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "POS 80%)- TSHA: Readthrough from add'l interim ph.I/II Rett data from NGNE's NGN-401 2H25 (stock +/-30%; POS 75% for TSHA)- TVTX: Advisory committee meeting ahead of Filsipari FSGS PDUFA likely 4Q25 (",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "ebebe5ac77f9ac4f",
        "value": 0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "TSHA: Readthrough from add'l interim ph.I/II Rett data from NGNE's NGN-401 2H25 (stock +/-30%; POS 75% for TSHA)- TVTX: Advisory committee meeting ahead of Filsipari FSGS PDUFA likely 4Q25 (stock +/-3",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "f3058764a1bc2727",
        "value": -0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "75% for TSHA)- TVTX: Advisory committee meeting ahead of Filsipari FSGS PDUFA likely 4Q25 (stock +/-30%; POS 70%)- TVTX: Filsipari approval for FSGS (1/13/2026) (stock +75%/-30%; POS 70%)- VALN: Full ",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "d64790ca2a9b3f4b",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "SHA)- TVTX: Advisory committee meeting ahead of Filsipari FSGS PDUFA likely 4Q25 (stock +/-30%; POS 70%)- TVTX: Filsipari approval for FSGS (1/13/2026) (stock +75%/-30%; POS 70%)- VALN: Full randomize",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "39b10a056a656351",
        "value": 0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "SGS PDUFA likely 4Q25 (stock +/-30%; POS 70%)- TVTX: Filsipari approval for FSGS (1/13/2026) (stock +75%/-30%; POS 70%)- VALN: Full randomized, controlled immunogenicity+safety data from ph.I for Zika",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "570a9ddd7a11fb7a",
        "value": -0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "DUFA likely 4Q25 (stock +/-30%; POS 70%)- TVTX: Filsipari approval for FSGS (1/13/2026) (stock +75%/-30%; POS 70%)- VALN: Full randomized, controlled immunogenicity+safety data from ph.I for Zika 2H25",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "5d4ba59f03841cf7",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "y 4Q25 (stock +/-30%; POS 70%)- TVTX: Filsipari approval for FSGS (1/13/2026) (stock +75%/-30%; POS 70%)- VALN: Full randomized, controlled immunogenicity+safety data from ph.I for Zika 2H25 (stock +2",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "7893748c94b9ba3e",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "S 70%)- VALN: Full randomized, controlled immunogenicity+safety data from ph.I for Zika 2H25 (stock +20%/-5%; POS 60%)- VALN: S4V2 infant ph.II safety+immunogenicity data 2H25 (stock +/-10%; POS 60%)-",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "d78259b0a72f51fc",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")- VALN: Full randomized, controlled immunogenicity+safety data from ph.I for Zika 2H25 (stock +20%/-5%; POS 60%)- VALN: S4V2 infant ph.II safety+immunogenicity data 2H25 (stock +/-10%; POS 60%)- VALN",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "c6c35478e9149dcf",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Full randomized, controlled immunogenicity+safety data from ph.I for Zika 2H25 (stock +20%/-5%; POS 60%)- VALN: S4V2 infant ph.II safety+immunogenicity data 2H25 (stock +/-10%; POS 60%)- VALN: Topline",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "7cf04da77cf5f438",
        "value": -0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ka 2H25 (stock +20%/-5%; POS 60%)- VALN: S4V2 infant ph.II safety+immunogenicity data 2H25 (stock +/-10%; POS 60%)- VALN: Topline from VLA15 Lyme ph.III w/ partner PFE YE25 (stock +35%/-25%; POS 75%)-",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "f7856750a8cbef33",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tock +20%/-5%; POS 60%)- VALN: S4V2 infant ph.II safety+immunogenicity data 2H25 (stock +/-10%; POS 60%)- VALN: Topline from VLA15 Lyme ph.III w/ partner PFE YE25 (stock +35%/-25%; POS 75%)- VERA: Rea",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "08bd733b70d5a769",
        "value": 0.35,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "data 2H25 (stock +/-10%; POS 60%)- VALN: Topline from VLA15 Lyme ph.III w/ partner PFE YE25 (stock +35%/-25%; POS 75%)- VERA: Readthroughs from Otsuka's sibeprenilimab IgAN approval and label 11/28/25",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "41231ed1f71d2d34",
        "value": -0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2H25 (stock +/-10%; POS 60%)- VALN: Topline from VLA15 Lyme ph.III w/ partner PFE YE25 (stock +35%/-25%; POS 75%)- VERA: Readthroughs from Otsuka's sibeprenilimab IgAN approval and label 11/28/25 (sto",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "6466d0bc79e2c08d",
        "value": 0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ck +/-10%; POS 60%)- VALN: Topline from VLA15 Lyme ph.III w/ partner PFE YE25 (stock +35%/-25%; POS 75%)- VERA: Readthroughs from Otsuka's sibeprenilimab IgAN approval and label 11/28/25 (stock +30%/-",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "15d9077c8b479448",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "; POS 75%)- VERA: Readthroughs from Otsuka's sibeprenilimab IgAN approval and label 11/28/25 (stock +30%/-15%; POS 60%) ## Upcoming med confs:",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "9b70abfbe9d8629d",
        "value": -0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "75%)- VERA: Readthroughs from Otsuka's sibeprenilimab IgAN approval and label 11/28/25 (stock +30%/-15%; POS 60%) ## Upcoming med confs:",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "3fff364df2bc84c4",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "A: Readthroughs from Otsuka's sibeprenilimab IgAN approval and label 11/28/25 (stock +30%/-15%; POS 60%) ## Upcoming med confs:",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "32f70517465d52ff",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "c4ee129eaaa26bd1",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not ",
        "provenance": {
          "page": 8
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 0,
      "tables_count": 0,
      "numerical_data_count": 99,
      "passages_count": 43,
      "entities_count": 20
    }
  }
}